BioCatalystWatch
TRAXWorkspace / TRAX / OverviewCompany library
FIRST TRACKS BIOTHERAPEUTICS, INC. logo

FIRST TRACKS BIOTHERAPEUTICS, INC.

FIRST TRACKS BIOTHERAPEUTICS, INC. (TRAX)

Website

Price
Market cap
Next catalystCohort 1 results presentation at ICDS, Melbourne, in November 2026ANB033 — celiac disease Phase 1b, Cohorts 1 and 2 · Phase 1 dataCompany release ↗
Cash

Chart & Events

Candle interval

Core Clinical

ANB033

CD122 (IL-2Rβ)

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

ANB033

CD122 (IL-2Rβ)

PreINDP1P2P3FilingApproved
Upcoming / outlook

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

ANB033

CD122 (IL-2Rβ)

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

ANB033

CD122 (IL-2Rβ)

PreINDP1P2P3FilingApproved
Upcoming / outlook

Other pipelines

History / paused

BDCA2

PreINDP1P2P3FilingApproved

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



Reported shares and borrowings

Source and basis

Source and basis

Source and basis

Source and basis

Ownership and institutions

Market Reaction / Supply Context

Market Structure

TRAX PR & News

PR & News

TRAX SEC archive